A detailed history of Marshall Wace, LLP transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 68,591 shares of CTKB stock, worth $384,109. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,591
Holding current value
$384,109
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$6.29 - $9.15 $431,437 - $627,607
68,591 New
68,591 $460,000
Q2 2022

Aug 15, 2022

BUY
$7.41 - $11.56 $400,851 - $625,349
54,096 New
54,096 $582,000
Q1 2022

May 16, 2022

SELL
$9.89 - $17.25 $70,812 - $123,510
-7,160 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$16.14 - $25.04 $115,562 - $179,286
7,160 New
7,160 $117,000

Others Institutions Holding CTKB

About Cytek Biosciences, Inc.


  • Ticker CTKB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 134,627,008
  • Market Cap $754M
  • Description
  • Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...
More about CTKB
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.